(R,S)-3,5-DHPG is an agonist of group I metabotropic glutamate receptors (mGluRs).1 It induces phosphoinositol hydrolysis in MCB3901, also known as AV12-664, cells expressing human mGluR1a and mGluR5a in a concentration-dependent manner. (R,S)-3,5-DHPG (10 ?M) potentiates NMDA-induced depolarizations in rat hippocampal slices. Intrathecal administration of (R,S)-3,5-DHPG (300 nmol/animal) increases mean blood pressure in anesthetized rats.2 Intracerebroventricular administration of (R,S)-3,5-DHPG (1.5 ?mol/animal) induces seizures in rats.3
1.Fitzjohn, S.M., Bortolotto, Z.A., Palmer, M.J., et al.The potent mGlu receptor antagonist LY341495 identifies roles for both cloned and novel mGlu receptors in hippocampal synaptic plasticityNeuropharmacology37(12)144-1458(1998) 2.S.M., C., and García, M.d.C.Activation of spinal metabotropic glutamate receptors elicits cardiovascular responses in pentobarbital anesthetized ratsNaunyn Schmiedebergs Arch Pharmacol.366(4)343-349(2002) 3.Camón, L., Vives, P., de Vera, N., et al.Seizures and neuronal damage induced in the rat by activation of group I metabotropic glutamate receptors with their selective agonist 3,5-dihydroxyphenylglycineJ. Neurosci. Res.51(3)339-348(1998)